Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company is headquartered in Palo Alto, California.
| Revenue (TTM) | $30.25M |
| Gross Profit (TTM) | $19.65M |
| EBITDA | $-267.68M |
| Operating Margin | -782.00% |
| Return on Equity | 0.00% |
| Return on Assets | -74.30% |
| Revenue/Share (TTM) | $2.74 |
| Book Value | $-29.75 |
| Price-to-Book | 28.85 |
| Price-to-Sales (TTM) | 1.47 |
| EV/Revenue | 5.19 |
| EV/EBITDA | -2.64 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -67.80% |
| Shares Outstanding | $7.03M |
| Float | $5.27M |
| % Insiders | 17.56% |
| % Institutions | 13.48% |
Volatility is currently expanding